about
Rapalogs in cancer prevention: anti-aging or anticancer?A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KLong-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.A high-throughput, cell-based screening method for siRNA and small molecule inhibitors of mTORC1 signaling using the In Cell Western techniqueEnhancing mTOR-targeted cancer therapy.Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes.CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.[Translational research in head and neck cancer. Biological characteristics and general aspects].mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3Oncogene addiction in gliomas: implications for molecular targeted therapyNCI's provocative questions on cancer: some answers to ignite discussion.CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Emerging therapies for colorectal cancer.Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics.Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses.Nature vs nurture: interplay between the genetic control of telomere length and environmental factors.TOR links starvation responses to telomere length maintenance.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.Immunosuppressants in cancer prevention and therapyRapamycin: killing two birds with one stone.Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes.Development of in-cell Western assays using far-red fluorophores.
P2860
Q26866151-EFED0C1E-630A-4C7F-BC6D-3B5A396FD071Q30301096-E7DEDC7B-71A8-4ACA-BECE-C14203DC99FCQ33414529-04B33B02-F19A-4A05-AA8B-91F57F54EFDFQ33525149-317F233C-8873-4193-9CC3-58B3F2958472Q33604979-94841DB2-96ED-46A2-8A8E-EC0AAEF1D0C4Q33757031-F7FCB54A-0533-4ABF-BC34-5CE526F45F4EQ33909085-2AF1F8A8-5AFF-49ED-86E0-043A0C9BA176Q34000961-97680B74-BC42-4D0D-823C-A0C803CD9EAAQ34231591-1F4DD8C1-30F3-4F39-BD45-8B6622594A43Q35041529-BA710CF3-66E4-40B5-BCAF-37A500A2C6CEQ35764401-45D6B26D-50B0-469B-BF08-249F8D92FE0AQ35987292-71B9C5F4-3354-46A3-9FD4-8AB7B8791BF5Q36462100-4E2FF00C-A5D1-48A1-BCD1-75FDE2347C3DQ36671809-D37464EE-AAC0-40B3-BF26-63BF57F3ABA6Q36736362-6EC280B9-5C94-4DC0-9FC9-B7A5ED7DAED7Q36821373-05B2359D-8F02-430D-9D67-E4A7AE7EB13AQ36950815-7BBE2272-FDD0-4AAB-B0AC-318AD8A7D21FQ37396834-B2C5CE93-EDF5-4117-ABB3-D3118F1A7B13Q37530242-D6BAE3E6-0A31-420B-9564-E139FE01E1AEQ38012251-171D65D8-373E-4C8C-BD2E-684A0FB635F6Q38729111-FA250BD9-4ECE-4810-B620-484283C30F47Q38964540-651B32A2-96F9-4D04-BC21-C6D80182AE2CQ39119297-24D59C70-F216-44BA-9975-05365E81BF7FQ40280414-80C76885-48FB-4814-BDEE-72F111DA4E01Q40853007-B221290A-3B9D-4B20-A44C-D0C5CAEA9A8DQ42505783-84878942-0385-4D8B-9B89-5414D96DF523Q43043684-3168B911-513D-4BC4-89CF-AD626ADE4CE6Q46202292-B266972B-C461-4B87-B609-EA3B10EBB759Q50544450-CC73D120-15DD-49F6-ABDD-EDD1ABACB3DC
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
TORgeting oncogene addiction for cancer therapy.
@en
TORgeting oncogene addiction for cancer therapy.
@nl
type
label
TORgeting oncogene addiction for cancer therapy.
@en
TORgeting oncogene addiction for cancer therapy.
@nl
prefLabel
TORgeting oncogene addiction for cancer therapy.
@en
TORgeting oncogene addiction for cancer therapy.
@nl
P1433
P1476
TORgeting oncogene addiction for cancer therapy.
@en
P2093
Andrew Y Choo
John Blenis
P356
10.1016/J.CCR.2006.01.021
P577
2006-02-01T00:00:00Z